These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 22108915

  • 1. Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study.
    Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA.
    Eur J Endocrinol; 2012 Feb; 166(2):207-13. PubMed ID: 22108915
    [Abstract] [Full Text] [Related]

  • 2. Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism.
    van der Klaauw AA, Biermasz NR, Zelissen PM, Pereira AM, Lentjes EG, Smit JW, van Thiel SW, Romijn JA, Roelfsema F.
    Eur J Endocrinol; 2007 Dec; 157(6):709-16. PubMed ID: 18057377
    [Abstract] [Full Text] [Related]

  • 3. Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women.
    Birzniece V, Magnusson NE, Ho KK, Frystyk J.
    Eur J Endocrinol; 2014 Mar; 170(3):375-83. PubMed ID: 24347426
    [Abstract] [Full Text] [Related]

  • 4. A switch from oral (2 mg/day) to transdermal (50 microg/day) 17beta-estradiol therapy increases serum insulin-like growth factor-I levels in recombinant human growth hormone (GH)-substituted women with GH deficiency.
    Janssen YJ, Helmerhorst F, Frölich M, Roelfsema F.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):464-7. PubMed ID: 10634425
    [Abstract] [Full Text] [Related]

  • 5. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women.
    Weissberger AJ, Ho KK, Lazarus L.
    J Clin Endocrinol Metab; 1991 Feb; 72(2):374-81. PubMed ID: 1991807
    [Abstract] [Full Text] [Related]

  • 6. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women.
    Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK.
    Am J Physiol Endocrinol Metab; 2001 Dec; 281(6):E1191-6. PubMed ID: 11701433
    [Abstract] [Full Text] [Related]

  • 7. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ, Fisker S, Gravholt CH, Bennett P, Svenstrup B, Andersen M, Feldt-Rasmussen U, Christiansen JS, Jørgensen JO.
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [Abstract] [Full Text] [Related]

  • 8. Estrogen replacement in women of fertile years with hypopituitarism.
    Mah PM, Webster J, Jönsson P, Feldt-Rasmussen U, Koltowska-Häggström M, Ross RJ.
    J Clin Endocrinol Metab; 2005 Nov; 90(11):5964-9. PubMed ID: 16091478
    [Abstract] [Full Text] [Related]

  • 9. Effects of transdermal and oral estrogen replacement on lipids and glucose metabolism in postmenopausal women with type 2 diabetes mellitus.
    Araújo DA, Farias ML, Andrade AT.
    Climacteric; 2002 Sep; 5(3):286-92. PubMed ID: 12419087
    [Abstract] [Full Text] [Related]

  • 10. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak.
    Feldt-Rasmussen U, Brabant G, Maiter D, Jonsson B, Toogood A, Koltowska-Haggstrom M, Rasmussen AK, Buchfelder M, Saller B, Biller BM.
    Eur J Endocrinol; 2013 May; 168(5):733-43. PubMed ID: 23416951
    [Abstract] [Full Text] [Related]

  • 11. The impact of dose and route of estrogen administration on the somatotropic axis in normal women.
    Lissett CA, Shalet SM.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4668-72. PubMed ID: 14557438
    [Abstract] [Full Text] [Related]

  • 12. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex.
    Kam GY, Leung KC, Baxter RC, Ho KK.
    J Clin Endocrinol Metab; 2000 May; 85(5):1918-22. PubMed ID: 10843175
    [Abstract] [Full Text] [Related]

  • 13. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency.
    Giavoli C, Profka E, Verrua E, Ronchi CL, Ferrante E, Bergamaschi S, Sala E, Malchiodi E, Lania AG, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P.
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3983-8. PubMed ID: 22904173
    [Abstract] [Full Text] [Related]

  • 14. Effects of GH replacement in young patients with childhood onset GH deficiency.
    Christiansen JS, Vahl N, Nørrelund H, Jørgensen JO.
    Int J Clin Pract Suppl; 2002 May; (126):32-6. PubMed ID: 12090699
    [No Abstract] [Full Text] [Related]

  • 15. Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.
    Birzniece V, Meinhardt U, Gibney J, Johannsson G, Baxter RC, Seibel MJ, Ho KK.
    J Clin Endocrinol Metab; 2010 May; 95(5):2099-106. PubMed ID: 20207825
    [Abstract] [Full Text] [Related]

  • 16. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study.
    Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2848-53. PubMed ID: 8768841
    [Abstract] [Full Text] [Related]

  • 17. Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.
    Birzniece V, Meinhardt UJ, Gibney J, Johannsson G, Armstrong N, Baxter RC, Ho KK.
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1005-12. PubMed ID: 22170716
    [Abstract] [Full Text] [Related]

  • 18. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F, Unluhizarci K, Kula M, Guven M, Bayram F, Kelestimur F.
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [Abstract] [Full Text] [Related]

  • 19. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults.
    Cenci MC, Conceição FL, Soares DV, Spina LD, Brasil RR, Lobo PM, Michmacher E, Vaisman M.
    Metabolism; 2008 Jan; 57(1):121-9. PubMed ID: 18078869
    [Abstract] [Full Text] [Related]

  • 20. Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy.
    Raudaskoski T, Knip M, Laatikainen T.
    Menopause; 1998 Jan; 5(4):217-22. PubMed ID: 9872487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.